Debuts new product name, ColdBlue^TM; demonstrates this cooled CCD camera as well as photon detectors, photocathodes and spectrometers in booth #2459

Fremont, CA -- March 10, 2003 -- PerkinElmer Optoelectronics, a global technology leader providing market-driven integrated solutions for biomedical and industrial markets, will demonstrate several just-released technologies at this week's annual Pittsburgh Conference (PITTCON) in Orlando, Florida. (Booth #2459). In addition, Company experts will lead two presentations to educate attendees on how recent technological innovations can improve the design, development, and performance of biomedical and analytical applications.

Nick Bertone, manager for High-Performance Detectors at PerkinElmer Optoelectronics, will present a paper at the New Product Forum entitled, "Single Photon Counting with Focus on Biomedical Applications," at 3:35 p.m., Sunday, March 9, 2003 at the Orange County Convention Center. Bertone will present examples of the Company's new four-channel SPCM array for Single Molecule Detection applications.

At 4:25 p.m. on Thursday, March 13, 2003, Dr. Raimund Barden, PerkinElmer's R&D manager for Photomultiplier Tubes, will present Session 2340 on "New Low-Noise Channel Photomultiplier Types for Biomedical and Analytical Applications," also at the Orange County Convention Center. This presentation will demonstrate how low-noise CPM types are ideal photon detection solutions for biomedical applications using fluorescence and luminescence techniques, such as in-vitro immunoassays.

In booth #2459, PerkinElmer will showcase the following technologies:

• SPCM-AQ4C Photon Detector - The industry's only four-channel photon counting card capable of detecting single photons over a wavelength range of 400nm to 1100nm, the AQ4C can be used for a range of applications that require examination of minute samples, including single molecule detection, high-throughput DNA sequencing, laser radars (LIDAR), adaptive optics and ultra-sensitive fluorescence detection. The four-channel array allows OEMs to provide four times the throughput with half the footprint and reduced power consumption, and enables researchers to test four wavelengths (or colors) at a time, saving time and improving accuracy in drug discovery and genomic research.
• C 992 Channel Photomultiplier - Offering the latest in photocathode technology, PerkinElmer's low-noise, yellow-enhanced CPM provides outstanding detection capabilities enabling scientists and researchers to locate smaller traces of material with an extended spectral range of 165 or 185 to 750 nm, making it ideal for luminescence and fluorescence applications such as blood analysis, gene assays, and cellomic research.
• ColdBlue™ Cooled CCD Camera - With a pixel resolution of 2184 x 1472, a 16-bit dynamic range that allows users to detect the faintest of signals and a cool new name, PerkinElmer's ColdBlue™ excels in such applications as protein quantification, fluorescent microscopy, and luminescence.
• UV/VIS and NIR Spectrometers - PerkinElmer customizes these high-performance spectrometer engines, which operate in the UV/VIS and near infrared (NIR) wavelength ranges, to provide integrated solutions for biomedical OEMs.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) fluctuations in the global economic and political environments; (4) markets into which we sell our products decline or do not grow as anticipated; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) our ability to produce an adequate quantity of products to meet our customers' demands; (12) the manufacture and sale of products may expose us to product liability claims; (13) our failure to maintain compliance with applicable government regulations; (14) regulatory changes; (15) our failure to comply with health care industry regulations; (16) economic, political and other risks associated with foreign operations; (17) our ability to retain key personnel; (18) restrictions in our credit agreements; (19) our ability to realize the full value of our intangible assets; (20) significant fluctuations in our stock price; and (21) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2 billion in 2008, has around 8,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

		For Further Information:
		Media Contact: Kristen Kmetetz Porter Novelli Life Sciences 617.897.8272 (office) Kristen.kmetetz@porternovelli.com or Francine S. Bernitz Marketing Director, Illumination and Detection Solutions PerkinElmer, Inc. Francine.bernitz@perkinelmer.com 978.224.4321 (office) 781.789.3178 (cell)